Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bcl-2 expression and apoptosis in nephrotoxic nephritis.
Sugiyama H, Kashihara N, Onbe T, Yamasaki Y, Wada J, Sekikawa T, Okamoto K, Kanao K, Maeshima Y, Makino H. Sugiyama H, et al. Among authors: sekikawa t. Exp Nephrol. 1997 Nov-Dec;5(6):481-9. Exp Nephrol. 1997. PMID: 9438177
Phenotypic changes of the mesangium in diabetic nephropathy.
Makino H, Kashihara N, Sugiyama H, Kanao K, Sekikawa T, Shikata K, Nagai R, Ota Z. Makino H, et al. Among authors: sekikawa t. J Diabetes Complications. 1995 Oct-Dec;9(4):282-4. doi: 10.1016/1056-8727(95)80022-7. J Diabetes Complications. 1995. PMID: 8573747
Role of apoptosis in the progression of glomerulosclerosis.
Makino H, Kashihara N, Sugiyama H, Sekikawa T, Ota Z. Makino H, et al. Among authors: sekikawa t. Contrib Nephrol. 1996;118:41-7. doi: 10.1159/000425074. Contrib Nephrol. 1996. PMID: 8744038 Review. No abstract available.
Expression of interleukin-8 in human glomerulonephritis.
Sekikawa T, Kashihara N, Maruyama K, Satoh M, Okamoto K, Kanao K, Maeshima Y, Sugiyama H, Yamasaki Y, Makino H. Sekikawa T, et al. Res Commun Mol Pathol Pharmacol. 1998 Feb;99(2):217-24. Res Commun Mol Pathol Pharmacol. 1998. PMID: 9583095
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
159 results